{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-006266","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.161080+00:00","generated_at":"2026-05-16T11:23:34.942582+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Phathom reports preliminary Q4 2025 revenue $57-58M; full year $174.5-175.5M; VOQUEZNA surpasses 1M prescriptions","bullets":["Q4 2025 net revenues expected ~$57-58M; full year 2025 net revenues ~$174.5-175.5M.","GAAP operating expenses Q4: ~$59-61M; non-GAAP (excl. stock-based comp) ~$51-53M.","Cash and equivalents ~$130M as of 12/31/25; net cash usage in Q4 ~$6M.","VOQUEZNA products surpassed 1 million prescriptions dispensed in U.S. during Q4.","Operating profitability (excl. stock-based comp) anticipated in second half of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-006266","json":"https://secwatch.observer/filing/0001193125-26-006266.json","markdown":"https://secwatch.observer/filing/0001193125-26-006266.md","text":"https://secwatch.observer/filing/0001193125-26-006266.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526006266/0001193125-26-006266-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312526006266/d52798d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:23:34.942582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}